A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
ConditionProteinuric Kidney Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-68
SponsorMaze Therapeutics
About this trial
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
Eligibility criteria
Qualifiers
APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
Chronic kidney disease with persistent albuminuria
Disqualifiers
Organ or bone marrow transplantation
History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
Conditions that may alter drug absorption, e.g., history of bariatric surgery
Type I diabetes
Trial design
Treatments tested in this trial
- MZE829
Treatment groups
74 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov